Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GM102 + carboplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Exelixis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
GM102 + carboplatin + paclitaxel is an investigational **combination cancer therapy** under clinical development, primarily for gynecological and solid tumors. GM102 (murlentamab) is a first-in-class, humanized, low-fucose monoclonal antibody targeting the Anti-Müllerian hormone type II receptor (AMHR2/AMHRII), which is selectively expressed in certain tumors. GM102 acts through engaging macrophages for anti-tumoral cytotoxicity. Carboplatin is a platinum-based chemotherapy agent that induces DNA cross-linking and apoptosis in rapidly dividing cells. Paclitaxel is a microtubule inhibitor (a plant-derived mitotic inhibitor) that disrupts cell division. Together, this combination aims to both boost anti-tumor immune response (via GM102) and directly kill cancer cells through established chemotherapeutic mechanisms (carboplatin, paclitaxel)[1][4][5].
- Other names
- murlentamab + carboplatin + paclitaxel
02
Targets
AMHR2 (Anti-Müllerian hormone receptor type 2)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on GM102 + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GM102 + carboplatin + paclitaxel.